Published Paper Details:

Chronic obstructive pulmonary disease (COPD) is a common, preventable and treatable chronic lung disease which affects men and women worldwide. Formoterol is a LABA,decreases resistance in the respiratory airway and increases airflow to the lungs. Budesonide is a corticosteroid, has a potent anti-inflammatory activity.Glycopyrronium is a LAMA, competitively blocks muscarinic receptors thus inhibiting cholinergic transmission.Spirometry is the essential test to assess how well your lungs work by measuring how much air you inhale, how much you exhale & how quickly you exhale.St. George Respiratory Questionnaire (SGRQ) is a disease-specific instrument designed to measure impact on overall health, daily life & perceived well-being in patients with obstructive airways disease. METHODS: The study was carried out in 50 patients with COPD. The study was conducted by categorising them into two groups, 25 patients taking Formoterol/Budesonide and 25 patients taking Formoterol/Glycopyrronium.The efficacy of drugs are assessed using spirometry and health related QOL is assessed using SGRQ-C. RESULT: By using spirometry, it was found that Formoterol/Glycopyrronium showed improvement in patients. A significant increase in the QOL was found in patients taking Formoterol/Glycopyrronium using SGRQ-C. CONCLUSION: It was concluded that, Formoterol/Glycopyrronium is slightly more efficient than Formoterol/Budesonide. There is a significant improvement in the QOL scoring in patients taking Formoterol/Glycopyrronium when compared to that of patients taking Formoterol/Budesonide.